Novocure Q3 net loss narrows 72% to USD 10.44 million

By Public Technologies
  • Novocure’s third-quarter 2026 net loss narrowed 72% year over year to $10.44 million.
  • Net revenues rose 16% year over year to $193.4 million, driven by 19% growth in global active patients.
  • Optune Pax secured Japanese approval in October for adults with unresectable locally advanced pancreatic cancer, alongside gemcitabine and nab-paclitaxel.
  • Full-year 2026 net revenues guidance increased to $736 million–$743 million from $710 million–$725 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610290700BIZWIRE_USPR_____20261029_BW363518) on October 29, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.